| Gene Symbol |
NDUFS5 |
| Full Name |
NADH:Ubiquinone Oxidoreductase Core Subunit S5 |
| Alias |
15 kDa subunit, CI15 |
| Chromosomal Location |
1p33 |
| NCBI Gene ID |
4723 |
| Ensembl ID |
ENSG00000168653 |
| OMIM ID |
603835 |
| UniProt ID |
O43920 |
| Protein Family |
Complex I accessory subunits |
| Associated Diseases |
[Parkinson's Disease](/diseases/parkinsons-disease), Leigh Syndrome, Mitochondrial Complex I Deficiency, [Alzheimer's Disease](/diseases/alzheimers-disease) |
NDUFS5 (NADH:Ubiquinone Oxidoreductase Core Subunit S5), also known as the 15 kDa subunit or CI-15, encodes an accessory subunit of mitochondrial complex I (NADH:ubiquinone oxidoreductase), the largest enzyme of the mitochondrial electron transport chain brandt1999. Located on chromosome 1p33, NDUFS5 plays a structural role in complex I assembly and function, and its dysfunction contributes to neurodegenerative processes including Parkinson's disease (PD) and Alzheimer's disease (AD) schapira2010.
Mitochondrial complex I (NADH dehydrogenase) is the first enzyme of the mitochondrial electron transport chain, catalyzing the oxidation of NADH and the reduction of coenzyme Q10 (ubiquinone). This pumping action establishes the proton gradient that drives ATP synthesis. Complex I dysfunction is a hallmark of PD, with selective loss of complex I activity in the substantia nigra of PD patients.
Mitochondrial complex I (NCI) is the largest oxidative phosphorylation complex, consisting of 44 different subunits janssen2006:
- 7 Core (FMN-containing) subunits: Form the catalytic core
- 13 Iron-sulfur (FeS) clusters: Enable electron transfer
- 31 Accessory subunits: Structural stability and assembly
NDUFS5 is an accessory subunit (~15 kDa) located in the Q module of complex I:
Core Functions of NDUFS5:
- Complex I assembly: Essential for proper assembly of the Q-binding module distelmaier2009
- Electron transfer: Facilitates electron transfer within the complex
- Structural stability: Contributes to the overall architecture of complex I
- Substrate binding: Assists in NADH and CoQ binding
- Proton pumping: Cooperates with core subunits for proton translocation
Complex I catalyzes two coupled reactions:
- NADH oxidation: NADH transfers electrons to FMN
- Electron transfer: 8 Fe-S clusters pass electrons to CoQ
- Proton pumping: 4 protons pumped per NADH oxidized
NDUFS5 participates in these processes by:
- Stabilizing the Q-binding site
- Maintaining proper Fe-S cluster configuration
- Ensuring coupling between electron transfer and proton pumping
In neurons, complex I is critical for chang2014:
Energy Production
- ATP generation for ion homeostasis
- Maintenance of membrane potentials
- Neurotransmitter synthesis and release
- Synaptic function and plasticity
Cellular Signaling
- Reactive oxygen species (ROS) as signaling molecules
- Calcium handling and mitochondrial calcium uptake
- Metabolic regulation through ATP/ADP ratios
Neuronal Survival
NDUFS5 is strongly implicated in PD gandhi2009:
Disease Mechanisms:
- Complex I deficiency: 30-40% reduction in complex I activity in substantia nigra
- Electron transport defects: Impaired NADH oxidation and CoQ reduction
- ROS overproduction: Increased superoxide radical formation
- Dopaminergic neuron vulnerability: Selective sensitivity to energy failure
Genetic Associations:
- NDUFS5 polymorphisms: Associated with increased PD risk
- Compound heterozygosity: Multiple rare variants cause manifests disease
- Mitochondrial DNA interactions: Synergistic effects with mtDNA mutations
Therapeutic Implications:
- Coenzyme Q10 supplementation
- Nicotinamide riboside (NAD+ precursor)
- Mitochondria-targeted antioxidants wang2022
- Gene therapy approaches
Complex I dysfunction is also observed in AD moreno2019:
- Amyloid-beta effects: Direct inhibition of complex I
- Tau pathology mitochondrial dysfunction: Cross-talk between tau and complex I
- Glucose hypometabolism: Correlates with complex I dysfunction
- Neuronal bioenergetic crisis: Progressive energy failure
NDUFS5 mutations cause classic Leigh syndrome koene2012:
Clinical Features:
- Progressive neurodegeneration: Characteristic brain lesions
- Developmental regression: Loss of achieved milestones
- Characteristic MRI findings: T2-hyperintense lesions in basal ganglia
- Lactic acidosis: Elevated blood and CSF lactate
Inheritance:
- Autosomal recessive
- Both alleles must carry pathogenic variants
Isolated complex I deficiency is the most common OXPHOS disorder vanbeerendonk2016:
- Phenotypes: Encephalomyopathy, cardiomyopathy, lactic acidosis
- NDUFS5 mutations: 15 kDa subunit deficiency
- NDUFS5 variants: Null alleles cause severe disease
- Residual activity: Correlates with phenotype severity
NDUFS5 is ubiquitously expressed:
- Brain: Highest in high-energy demand regions
- Heart: Very high expression in cardiac muscle
- Skeletal muscle: High expression for contractile function
- Kidney and liver: Moderate expression
- All tissues: Essential for cellular energy
NDUFS5 shows regional specificity:
- Substantia nigra: Dopaminergic neurons (vulnerable in PD)
- Cerebral cortex: Pyramidal neurons
- Hippocampus: CA1-CA3 neurons, dentate gyrus
- Cerebellum: Purkinje cells
- Brainstem: Motor neurons
- Neurons: High expression, especially projection neurons
- Astrocytes: Supporting metabolic functions
- Oligodendrocytes: Myelination energy demands
- Microglia: Activity-dependent regulation
NDUFS5 expression is regulated by chen2015:
- Nuclear respiratory factors (NRF-1, NRF-2): Transcriptional activation
- PGC-1α: Master regulator of mitochondrial biogenesis
- ERRα: Estrogen-related receptor alpha
- NAD+/SIRT1 axis: Metabolic sensing
Symptomatic Treatments:
- Coenzyme Q10 (100-300 mg/day)
- L-carnitine
- Creatine monohydrate
- Alpha-lipoic acid
Emerging Therapies:
- Nicotinamide riboside (NAD+ precursor)
- Mitochondria-targeted antioxidants (MitoQ)
- Gene replacement therapy
- Stem cell transplantation pitceathly2014
- Complex I activators: Enhance assembly and function
- Assembly chaperones: Promote proper complex I formation
- mTOR inhibitors: Activate mitophagy
- Metabolic modulators: Improve substrate utilization
- iPSC models: Patient-derived neurons for study
- Gene editing: CRISPR for mutation correction
- Drug screening: High-throughput compound libraries
- Biomarkers: Complex I activity as progression marker
¶ Interactions and Pathways
- Core complex I subunits: ND1, ND2, ND3, etc.
- NDUFAF1: Assembly factor
- NDUFAF2: Molecular chaperone
- NDUFAF4: Early assembly factor
- Mitochondrial dynamics: Fusion/fission balance
- Mitophagy: PINK1/Parkin-mediated clearance
- Mitochondrial DNA: Dependent on nuclear-encoded subunits
- ATP synthase: Downstream OXPHOS component
- mTOR signaling: Energy sensing
- AMPK pathway: Metabolic regulation
- SIRT1/NAD+ pathway: Metabolic sensing
- 凋亡途径: Apoptotic cascade activation
Complex I assembly follows an ordered pathway:
- Q module formation: ND1, ND2, ND3, ND6 with NDUFS5
- N module formation: Core NADH-binding subunits
- P module formation: Proton-pumping subunits
- Iron-sulfur cluster insertion: Sequential assembly
- Final assembly: Complete enzyme formation
NDUFS5 integrates into the Q module early in assembly:
- Pre-assembled subcomplex: Q-module precursor
- NDUFS5 incorporation: 15 kDa subunit addition
- Fe-S cluster transfer: [4Fe-4S] cluster insertion
- Completion: Functional complex I formation
Within complex I, electrons flow:
- NADH → FMN: Flavin mononucleotide accepts 2 electrons
- FMN → [Fe-S]: Electron transfer through Fe-S clusters
- [Fe-S] → CoQ: Ubiquinone reduction
- CoQ → Complex III: Q-cycle entry point
NDUFS5 contributes to this pathway by:
- Stabilizing the Q-binding pocket
- Maintaining Fe-S cluster integrity
- Ensuring proper electron flow
- Patient fibroblasts: For biochemical studies
- iPSC-derived neurons: Disease modeling
- Cybrid cell lines: mtDNA transfer studies
- Knockdown models: siRNA-mediated deficiency
- Zebrafish: Transparent for imaging
- Drosophila: Genetic tractability
- Mouse models: Mammalian physiology
- Conditional knockouts: Tissue-specific
- Blue-native PAGE: Complex I activity assays
- Spectrophotometry: Enzyme kinetics
- Oxygraphy: Oxygen consumption
- Mitochondrial respirometry: Seahorse analysis
- Genetic testing: Panel or whole-exome sequencing
- Biochemical testing: Complex I activity in muscle
- Neuroimaging: MRI for Leigh syndrome lesions
- Metabolic testing: Lactate, pyruvate levels
Complex I deficiency prognosis:
- Infantile onset: Most severe prognosis
- Late-onset: Variable progression
- Treatment response: Correlates with residual activity
- Autosomal recessive: 25% recurrence risk
- Carrier testing: For at-risk family members
- Prenatal diagnosis: For known mutations
- Preimplantation: For carrier families
- Atomic structure: Cryo-EM structures of complex I
- Assembly factors: Multiple chaperones identified
- Therapeutic targets: New drug candidates
- Gene therapy: Viral vector delivery
- Precise gene editing: CRISPR base editors
- Protein replacement: Encapsulated enzyme delivery
- Mitochondrial replacement: spindle transfer
- Combination therapies: Multi-target approaches